Product Images Gemcitabine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Gemcitabine NDC 0409-0186 by Hospira, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

structural formula gemcitabine - gemcitabine 01

structural formula gemcitabine - gemcitabine 01

Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine plus Carboplatin versus Carboplatin in Ovarian Cancer (N=356) - gemcitabine 02

Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine plus Carboplatin versus Carboplatin in Ovarian Cancer (N=356) - gemcitabine 02

Figure 2 - gemcitabine 03

Figure 2 - gemcitabine 03

The text is describing the results of a study or experiment that involved the drug Paclitaxel. The Log rank p-value is reported as 0.0001, which indicates statistical significance. The third line mentions something about "Time to Documented Disease Progression (Months)", but without further context it is difficult to determine what it means.*

Figure 3 - gemcitabine 04

Figure 3 - gemcitabine 04

This text contains statistical data related to the median survival time and survival probability for Gemcitabine/Cisplatin and Cisplatin, as well as statistical tests such as Logrank and Wilcoxon. However, it is not clear what type of study or research this data is from, as there is no additional context.*

Figure 4 - gemcitabine 05

Figure 4 - gemcitabine 05

This appears to be a graph displaying the "Fraction Surviving" over "Survival Time (months)" for a treatment named "Gemcitabine". The graph shows data points and a line representing the survival rate of individuals receiving Gemcitabine over the course of treatment. The graph is numbered by months and fractions, with the line starting at 0.8 at 10 months and decreasing to around 0.2 at 20 months.*

Hospira logo - gemcitabine 06

Hospira logo - gemcitabine 06

PRINCIPAL DISPLAY PANEL - 200 mg Vial Label - gemcitabine 07

PRINCIPAL DISPLAY PANEL - 200 mg Vial Label - gemcitabine 07

PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton - gemcitabine 08

PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton - gemcitabine 08

This is a product description of a drug called Gemcitabine, which is a Cytotoxic Agent. It comes in a single-dose vial containing 200mg Gemcitabine for Intravenous use only. The drug also contains 200mg Mannitol, and 125mg Sodium Acetate. The drug is reconstituted by adding 5 mL of 0.9% Sodium Chloride Injection to make a solution containing 38mg/mL. The solution should be administered within 24 hours and should be discarded if unused. The provided text also contains storage and usage instructions.*

PRINCIPAL DISPLAY PANEL - 1 g Vial Label - gemcitabine 09

PRINCIPAL DISPLAY PANEL - 1 g Vial Label - gemcitabine 09

PRINCIPAL DISPLAY PANEL - 1 g Vial Carton - gemcitabine 10

PRINCIPAL DISPLAY PANEL - 1 g Vial Carton - gemcitabine 10

Gemcitabine for Injection, USP is a cytotoxic agent that comes in a single-dose vial. Each 1 g vial contains 1 g gemcitabine, 1 g mannitol, and 625 mg sodium acetate. It is recommended to check the package insert for complete product information. To reconstitute, add 25 L of 0.9% Sodium Chloride Injection and shake to dissolve. The solution should be administered within 24 hours and any unused portion should be discarded. The storage temperature before and after reconstitution should be between 20 - 25°C. Gemcitabine Hydrochloride is potentially cytotoxic, so be cautious when handling it.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.